Evaluation of aztreonam in the treatment of severe bacterial infections
| Autor: | Emilio Bouza, J Romero-Vivas, J Martínez-Beltrán, Marta Rodríguez-Créixems, T Hellín, Antonio Guerrero, M García de la Torre |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 1985 |
| Předmět: |
Adult
medicine.medical_specialty Adolescent medicine.drug_class Antibiotics Aztreonam medicine.disease_cause Haemophilus influenzae chemistry.chemical_compound Internal medicine Medicine Humans Pharmacology (medical) Child Aged Pharmacology business.industry Streptococcus Pseudomonas aeruginosa Osteomyelitis Bacterial Infections Middle Aged medicine.disease Infectious Diseases chemistry Staphylococcus aureus Superinfection Bacteremia Immunology Urinary Tract Infections business Research Article |
| Popis: | We investigated the clinical efficacy and safety of aztreonam in the treatment of 50 episodes of infection in 46 adult patients. The clinical condition of patients at the beginning of treatment was critical or poor in 28 of the episodes of infection. Episodes treated were 39 urinary tract infections (12 of them with concomitant bacteremia), 2 soft tissue infections, 8 patients with osteomyelitis (1 with concomitant bacteremia), and one episode of pneumonia. Significant isolated microorganisms were aerobic or facultative gram-negative rods and were responsible for the following episodes of infection (number of episodes): members of the family Enterobacteriaceae (49), Pseudomonas aeruginosa (5), and Haemophilus influenzae (1). The overall rate of clinical response to aztreonam was 94% of the treated episodes. Colonization or superinfection or both occurred in 29 episodes, but only 8 episodes required antimicrobial therapy. Aztreonam seems to be an effective single agent therapy for many bacterial infections. Colonization and superinfection by Candida sp., Streptococcus faecalis or Staphylococcus aureus must be monitored. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|